Antitrust

Challenging global giants, a Korean app marketplace has secured the #2 spot by slashing developer fees and rewarding users, rewriting the rules of app economics.

A new class action lawsuit accuses medical device firm Integer Holdings of hiding poor sales while touting growth, leading to a major stock drop.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

Amid rising legal threats, a new coalition offers free legal aid to Canadian journalists, aiming to protect press freedom and empower local reporting.

Westgate Resorts gets a major endorsement for family travel in Orlando. We dive into what makes them stand out and the business of online reviews.

As winter storms loom, a silent threat enters our homes. Learn the critical, life-saving steps to protect your family from carbon monoxide and fire.

Recent CPSC warnings reveal deadly products on the market. As regulators struggle with e-commerce, can AI become the tool we need to stop them?

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

BTCC's integration with TradingView signals a major industry shift, bringing professional-grade tools and seamless execution to the crypto futures market.

On Human Rights Day, Ottawa touts global leadership, but a chasm grows between its international promises and the stagnant progress on justice at home.

A new federal hemp ban is set to fail, warns a CRS report. Experts say a lack of funding and data infrastructure could create a dangerous black market.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

Promising long-term data and key regulatory wins position Wugen's allogeneic therapy to disrupt the challenging T-cell cancer treatment landscape.

With a high-grade Alaskan asset secured and a $44M war chest, Vizsla Copper is making a bold move in the race for North American resource security.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.